Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Prednisone Discontinuation in Quiescent Systemic Lupus
NCT02558517Phase 3Unknown
- Sponsor
- La Pitié-Salpêtrière Hospital
- Start
- Jan 2014
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of prednisone in systemic lupus erythematosus (SLE) (2 arms), sponsored by La Pitié-Salpêtrière Hospital. Primary endpoint: Occurrence of mild or moderate flares of SLE defined by the SLE FLARE Index at 12 months. Status: unknown.
02
Drugs
prednisone
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02558517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558517.